JAGX Jaguar Health Inc.

2.82
-0.38  -12%
Previous Close 3.2
Open 2.86
Price To Book 1.01
Market Cap 6,889,252
Shares 2,442,997
Volume 670,078
Short Ratio
Av. Daily Volume 426,381

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 interim data due 1H 2019. Timeline missed. Assume 3Q 2019 release.
Mytesi (crofelemer) HALT-D
Cancer related diarrhea (CRD)
Protocol development for discussions with FDA.
Mytesi (crofelemer)
Inflammatory bowel disease (IBD)

Latest News

  1. Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million
  2. Jaguar Health's Wholly Owned Subsidiary, Napo Pharmaceuticals, Inc., Commits to Support Study Evaluating the Effect of Crofelemer on Patients With Chronic Idiopathic Diarrhea
  3. Jaguar Health Engages Integrium, LLC to Support Clinical Study Evaluating the Effect of Mytesi on the Microbiome
  4. The Daily Biotech Pulse: Genfit NASH Drug In China, Conatus Explores Sale, Gilead Stitches Up Immuno-Oncology Partnership
  5. Jaguar Health Regains Compliance with All Applicable Nasdaq Stock Market Listing Standards
  6. Jaguar Health Announces Key Finding for Final Canalevia Technical Section for Proposed Indication of Chemotherapy-Induced Diarrhea in Dogs
  7. Jaguar Health Announces Completion of Pilot Study in Dogs in Support of Future Clinical Investigations Evaluating Crofelemer for Treatment of Noninfectious Diarrhea in Human Cancer Patients Receiving Tyrosine Kinase Inhibitors
  8. Jaguar Health Subsidiary Receiving Preclinical Services Funded by the National Institute of Allergy and Infectious Diseases in Support of Development of Lechlemer Drug Product Candidate for Cholera Indication
  9. Jaguar Health, Inc. Announces 1-for-70 Reverse Stock Split
  10. Jaguar Health CEO and Board Members Invest in Bridge Financing
  11. Jaguar Health Refinances $10.5 Million of Secured Debt, Including an Extension of the Maturity of Such Debt from December 31, 2019 to December 31, 2020
  12. Jaguar Health Eliminates More Than $6.4 Million in Secured Promissory Notes to Strengthen Company's Balance Sheet
  13. Jaguar Health, Inc. Reports Voting Results from May 24, 2019 Annual Meeting of Stockholders
  14. Jaguar Health, Inc. Reports 2019 First Quarter Financial Results
  15. Jaguar Health Donates Supply of Mytesi to Humanitarian Aid Organization Direct Relief
  16. Jaguar Health, Inc. Reports 2018 Fourth Quarter and Year End Financial Results
  17. Jaguar Health Subsidiary Napo Pharmaceuticals Issues Further Regulatory Update Regarding Potential Follow-on Indication for Mytesi
  18. Jaguar Health, Pipeline Review and Progress
  19. Jaguar Health Issues Regulatory Update Regarding Potential Follow-on Indication for Mytesi